reports
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 19 February 2026
19th February 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: N...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 12 February 2026
* A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: None What’s baking in the oven? Market Movers:*** 14 January: GlobalData (DATA.L), the data, insight, and technology Company e...
Thermo Fisher Scientific Inc: 1 director
Two Directors at Thermo Fisher Scientific Inc sold 413 shares at between 0.000USD and 541.200USD. The significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Chop Continues; Nasdaq 100 Testing Major Resistance We maintain our near-term bullish outlook on the S&P 500 (SPX), Nasdaq 100 (QQQ), and Russell 2000 (IWM), which has remained in place since 4/22/25, aside from one week (11/19/25-11/25/25) when we went to neutral. We will stay near-term bullish as long as crucial support levels of 6824 on SPX, $610 on QQQ, and $245 on IWM continue to hold. We see mild deterioration in market dynamics, which may provide a near-term headwind; still, MAG7 earning...
SCCO SOUTHERN COPPER CORPORATION
FCX FREEPORT-MCMORAN INC.
LUN LUNDIN MINING CORPORATION
TECK.B TECK RESOURCES LIMITED CLASS B
HLX HELIX ENERGY SOLUTIONS GROUP INC.
OII OCEANEERING INTERNATIONAL INC.
OIS OIL STATES INTERNATIONAL INC.
RIGN TRANSOCEAN LTD.
TEC TECHNIPFMC PLC
TDW TIDEWATER INC
A2H5RW ERO COPPER
SOCA SUBSEA 7 S.A. ADS
VAL VALARIS LTD
BORR BRISTOW GROUP INC
NE BORR DRILLING LTD
INVX NOBLE CORP (NEW)
SDRL INNOVEX INTERNATIONAL INC
SEADRILL LTD
Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Developm...
Polarean Expands Xenon MRI Platform into Cardiopulmonary Drug Development with Multi-Center PH-ILD Study Innovative Trial Design to Directly Measure Microvascular Functional Effects of Inhaled Therapy at the Capillary level of Pulmonary Hypertension Patients with Interstitial Lung Disease (PH-ILD) DURHAM, NC and LONDON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Polarean, a commercial-stage medical imaging company advancing functional MRI of the lungs, today announced the expansion of its Xenon MRI platform into cardiopulmonary pharma-sponsored drug development through a multi-center U.S. study ...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 20 January 2026
20th January 2026 @HybridanLLP Our daily digest of news from UK Small Caps * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: None...
Polarean Highlights New CHEST Journal Study Demonstrating Xenon MRI Pr...
Polarean Highlights New CHEST Journal Study Demonstrating Xenon MRI Predicts Cystic Fibrosis Exacerbations Findings Show Xenon MRI Ventilation Defects Independently Predicts Exacerbation Risk Beyond Conventional Clinical Measures DURHAM, NC and London, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Polarean, a commercial-stage medical imaging company advancing functional MRI of the lungs, today highlighted the publication of a peer-reviewed clinical study in CHEST. The study demonstrates that structural and functional pulmonary MRI adds important new insights in predicting pulmonary exacerbations be...
XENOVIEW® 3T coil passes Philips compatibility testing
XENOVIEW® 3T coil passes Philips compatibility testing Polarean’s FDA cleared coil achieves important milestone, expanding clinical reach DURHAM, NC and LONDON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced Magnetic Resonance Imaging ("MRI") of the lungs, announces that its FDA-cleared XENOVIEW® 3T Chest Coil has successfully completed compatibility testing conducted by Philips (Philips Medical Systems Nederland B.V.) and is now confirmed for use with Philips’ latest 3T MRI platforms. Following extensive validat...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...
WAT WATERS CORPORATION
VCYT VERACYTE INC
TMO THERMO FISHER SCIENTIFIC INC.
RGEN REPLIGEN CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
IDXX IDEXX LABORATORIES INC.
HALO HALOZYME THERAPEUTICS INC.
EXEL EXELIXIS INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ANGO ANGIODYNAMICS INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
IONS IONIS PHARMACEUTICALS INC.
PKI PERKINELMER INC.
UTHR UNITED THERAPEUTICS CORPORATION
FLGT FULGENT GENETICS
MDGL MADRIGAL PHARMACEUTICALS
CELC CELCUITY
DNLI DENALI THERAPEUTICS INC
STE STERIS PLC
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
VIR VIR BIOTECHNOLOGY
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
PRPO PRECIPIO INC.
Korean distributor agreement with DK Healthcare in South Korea
Korean distributor agreement with DK Healthcare in South Korea Expanding commercial reach and advancing lung imaging innovation in Asia-Pacific DURHAM, NC and LONDON, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX) (“Polarean” or the “Company”), a commercial-stage medical imaging technology leader in functional Magnetic Resonance Imaging ("MRI") of the lungs, announces it has signed an exclusive distribution agreement with DK Healthcare Co., Ltd. (“DK Healthcare”) for the distribution of Polarean’s Xenon MRI platform in South Korea. This agreement represents Polare...
- Hybridan Team
- Jon Levinson
Hybridan Small Cap Feast: 24 November 2025
* A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the Day Admissions: None Delistings: On Friday 21st, Woodbois (WBI.L) left AIM. What’s baking in the oven? Potential** Initial Public Offerings:*** 24th Octobe...
- Colin Smith
Polarean Imaging | Proposed delisting from AIM market
Further to the strategic review announced on 22 October, Polarean has now formally proposed to delist from AIM and take the company private. The reasons cited by Polarean are: stronger access to capital, listing and compliance costs, public market undervaluation, and the current funding environment. Polarean reiterated its cash runway guidance through 2Q26 and its anticipated US$20m funding requirement. Cancellation from AIM is subject to a special resolution requiring a 75% vote in favour of th...
Kromek Group: 1 director
A director at Kromek Group maiden bought 285,000 shares at 6.7p and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Moody's Ratings says Thermo Fisher's Clario acquisition expands clinic...
Moody's Ratings commented that Thermo Fisher Scientific Inc.'s (A3 positive) announcement that it entered into a definitive agreement to acquire privately held Clario Holdings, Inc. for $8.88 billion plus certain potential future payouts will add scale and earnings diversity and bolster capabilities...
- Hybridan Team
- Jon Levinson
Friday Take Away: 10 October 2025
Friday Takeaway—delving a little deeper into UK small caps Friday Takeaway from UK Small Caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 10th October 2025 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication. Top three shareholders are taken from the webs...
- Hybridan Team
Hybridan Small Cap Feast: 06/10/2025
6th October 2025 @HybridanLLP * A corporate client of Hybridan LLP. ** Potential means Intention to Float (ITF) or similar announcement has been made. ***Arranged by type of listing and date of announcement. ****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication. Dish of the day Admissions: 6th October: Ashtead Technology (AT.L) announced it has moved from AIM to the Ma...
- Colin Smith
Polarean Imaging | Updates: NIH & UVA Health sales, Ascend expansion
Since the interim results, Polarean has made three further announcements including the sale of a complete Xenon MRI system to the National Institutes of Health Clinical Center, a significant follow on sale to the University of Virginia and, most recently, an expansion of the Representative Agreement it signed with Ascend Imaging (Ascend) in June. Collectively, we believe the new sales secure Polarean's current revenue guidance of US$2.5m-US$3.5m for 2025 and bode well for future sales announceme...
Moody's Ratings assigns A3 rating to Thermo Fisher's sr. unsecured not...
Moody's Ratings (Moody's) assigned an A3 rating to the new senior unsecured notes offering by Thermo Fisher Scientific Inc. (Thermo Fisher). There are no changes to Thermo Fisher's existing ratings including the A3 senior unsecured long-term ratings and the senior unsecured commercial paper Prime-2 ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.